• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Pivotal Shigella Vaccine Efficacy Trials-Study Design Considerations from a Vaccine Trial Design Working Group.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Pavlinac, Patricia B
    Rogawski McQuade, Elizabeth T
    Platts-Mills, James A
    Kotloff, Karen L
    Deal, Carolyn
    Giersing, Birgitte K
    Isbrucker, Richard A
    Kang, Gagandeep
    Ma, Lyou-Fu
    MacLennan, Calman A
    Patriarca, Peter
    Steele, Duncan
    Vannice, Kirsten S
    Show allShow less

    Date
    2022-03-22
    Journal
    Vaccines
    Publisher
    MDPI AG
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.3390/vaccines10040489
    Abstract
    Vaccine candidates for Shigella are approaching phase 3 clinical trials in the target population of young children living in low- and middle-income countries. Key study design decisions will need to be made to maximize the success of such trials and minimize the time to licensure and implementation. We convened an ad hoc working group to identify the key aspects of trial design that would meet the regulatory requirements to achieve the desired indication of prevention of moderate or severe shigellosis due to strains included in the vaccine. The proposed primary endpoint of pivotal Shigella vaccine trials is the efficacy of the vaccine against the first episode of acute moderate or severe diarrhea caused by the Shigella strains contained within the vaccine. Moderate or severe shigellosis could be defined by a modified Vesikari score with dysentery and molecular detection of vaccine-preventable Shigella strains. This report summarizes the rationale and current data behind these considerations, which will evolve as new data become available and after further review and consultation by global regulators and policymakers.
    Keyword
    Shigella
    low and middle-income countries
    pediatrics
    vaccine trial design
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/18661
    ae974a485f413a2113503eed53cd6c53
    10.3390/vaccines10040489
    Scopus Count
    Collections
    UMB Open Access Articles

    entitlement

    Related articles

    • The Clinical Presentation of Culture-positive and Culture-negative, Quantitative Polymerase Chain Reaction (qPCR)-Attributable Shigellosis in the Global Enteric Multicenter Study and Derivation of a Shigella Severity Score: Implications for Pediatric Shigella Vaccine Trials.
    • Authors: Pavlinac PB, Platts-Mills JA, Tickell KD, Liu J, Juma J, Kabir F, Nkeze J, Okoi C, Operario DJ, Uddin J, Ahmed S, Alonso PL, Antonio M, Becker SM, Breiman RF, Faruque ASG, Fields B, Gratz J, Haque R, Hossain A, Hossain MJ, Jarju S, Qamar F, Iqbal NT, Kwambana B, Mandomando I, McMurry TL, Ochieng C, Ochieng JB, Ochieng M, Onyango C, Panchalingam S, Kalam A, Aziz F, Qureshi S, Ramamurthy T, Roberts JH, Saha D, Sow SO, Stroup SE, Sur D, Tamboura B, Taniuchi M, Tennant SM, Roose A, Toema D, Wu Y, Zaidi A, Nataro JP, Levine MM, Houpt ER, Kotloff KL
    • Issue date: 2021 Aug 2
    • The Shigella Vaccines Pipeline.
    • Authors: MacLennan CA, Grow S, Ma LF, Steele AD
    • Issue date: 2022 Aug 24
    • WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report.
    • Authors: Hosangadi D, Smith PG, Kaslow DC, Giersing BK, WHO ETEC & Shigella Vaccine Consultation Expert Group
    • Issue date: 2019 Nov 28
    • Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    • Authors: Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG
    • Issue date: 2021 Apr
    • Could a Shigella vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a Shigella vaccine public health value proposition, March 24 and 29, 2021.
    • Authors: Bagamian KH, Puett C, Anderson JD 4th, Muhib F, Pecenka C, Behrman J, Breiman RF, Edoka I, Horton S, Kang G, Kotloff KL, Lanata CF, Platts-Mills JA, Qadri F, Rogawski McQuade ET, Sudfeld C, Vonaesch P, Wierzba TF, Scheele S
    • Issue date: 2022 Dec
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.